CompanyGraph
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
002693 · SZSE · China
shuangchengmed.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 5.35: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.91BCNY583.34M · vs all stocks (USD)
Trailing P/E
70.92xRevenue (TTM)
309.80MCNY46.26M · vs all stocks (USD)
Profit Margin
16.51%Beta
0.4810xvs all stocks
52-Week Change
26.27%vs all stocks
Market Capitalization
3.91BCNY583.34M · vs all stocks (USD)
Enterprise Value
4.06BCNY605.55M · vs all stocks (USD)
Trailing P/E
70.92xPrice to Sales (TTM)
12.34xPrice to Book (MRQ)
8.98xEnterprise to Revenue
13.09xEnterprise to EBITDA
39.33xGross Margin
50.85%Profit Margin
16.51%Operating Margin
15.03%Return on Assets (TTM)
3.97%Return on Equity (TTM)
9.99%Revenue (TTM)
309.80MCNY46.26M · vs all stocks (USD)
Revenue per Share (TTM)
0.8140CNYUpdated Sep 21, 2026Quarterly Revenue Growth
44.80%Gross Profit (TTM)
170.36MCNY25.44M · vs all stocks (USD)
EBITDA (TTM)
76.11MCNY11.37M · vs all stocks (USD)
Net Income (TTM)
51.14MCNY7.64M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
87.37%Operating Cash Flow (TTM)
83.05MCNY12.40M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
10.43MCNY1.56M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
8.07MCNYFY2025 · Dec 31, 2025Revenue
276.76MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
125.24MCNYFY2025 · Dec 31, 2025Gross Profit
151.53MCNYFY2025 · Dec 31, 2025Operating Income
24.06MCNY3.59M · vs all stocks (USD)
Pre-tax Income
8.16MCNYFY2025 · Dec 31, 2025Income Tax Expense
-764.41KCNYFY2025 · Dec 31, 2025Net Income
8.92MCNYFY2025 · Dec 31, 2025EBIT
17.80MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
76.11MCNYFY2025 · Dec 31, 2025Research & Development
8.09MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
46.39MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
156.37KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.65MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
380.86MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
380.86MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
8.92MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.12MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-18.97MCNYFY2025 · Dec 31, 2025Free Cash Flow
-61.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
59.05MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
8.92MCNYFY2025 · Dec 31, 2025Other Non-cash Items
11.96MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-51.02MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
11.17MCNYFY2025 · Dec 31, 2025Capital Expenditures
-42.21MCNYFY2025 · Dec 31, 2025Purchase of Investments
-199.60MCNYFY2025 · Dec 31, 2025Sale of Investments
199.88MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-41.93MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
29.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-28.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-7.27MCNYFY2025 · Dec 31, 2025Other Financing Charges
1.15MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.12MCNYFY2025 · Dec 31, 2025Shares Outstanding
414.69MSharesUpdated Sep 21, 2026Float Shares
343.92MSharesUpdated Sep 21, 2026% Held by Insiders
55.29%vs all stocks
% Held by Institutions
0.09%vs all stocks
Total Cash (MRQ)
40.33MCNY6.02M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0970CNYUpdated Sep 21, 2026Total Debt (MRQ)
268.66MCNY40.12M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6256xCurrent Ratio (MRQ)
0.6200xBook Value per Share (MRQ)
1.03CNYUpdated Sep 21, 2026Total Assets
825.78MCNY123.31M · vs all stocks (USD)
Total Current Assets
204.71MCNYFY2025 · Dec 31, 2025Total Liabilities
405.25MCNYFY2025 · Dec 31, 2025Total Non-current Assets
621.06MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
98.41MCNYFY2025 · Dec 31, 2025Total Current Liabilities
306.83MCNYFY2025 · Dec 31, 2025Cash
59.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
34.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
59.05MCNYFY2025 · Dec 31, 2025Other Short-term Investments
46.43KCNYFY2025 · Dec 31, 2025Accounts Receivable
62.21MCNYFY2025 · Dec 31, 2025Inventory
66.09MCNYFY2025 · Dec 31, 2025Accounts Payable
23.84MCNYFY2025 · Dec 31, 2025Short-term Debt
124.72MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.85MCNYFY2025 · Dec 31, 2025Long-term Debt
89.00MCNYFY2025 · Dec 31, 2025Common Stock (Book)
414.69MCNYFY2025 · Dec 31, 2025Retained Earnings
-406.22MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
420.53MCNY62.80M · vs all stocks (USD)
52-Week Low
6.36CNYUpdated Sep 21, 202652-Week High
12.43CNYUpdated Sep 21, 202652-Week Change
26.27%vs all stocks
Beta
0.4810xvs all stocks
50-Day MA
9.20CNYUpdated Sep 21, 2026200-Day MA
8.56CNYUpdated Sep 21, 2026Avg 10-Day Volume
12.49MSharesUpdated Sep 21, 2026Avg 30-Day Volume
17.63MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.1300CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.35: safe zoneNotable
Altman Z-Score: 5.35
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
OrthoPediatrics Corp.
Tier 1ProductionApproval-Gated PipelineRule